Stem cell therapy could reduce influenza-associated respiratory complications [PreClinical]

1. When the two cell types were cultured together, human mesenchymal stromal cells (MSCs) normalized the fluid and protein exchange functions of alveolar epithelial cells.

2. In a mouse model of influenza H5N1 infection, treatment with MSCs led to improved survival and disease pathology.

Evidence Rating Level: 2 (Good)

Study Rundown: Currently, there is a lack of effective treatments for acute lung injury as a result of respiratory virus infections. In this work, the authors demonstrated that MSCs, multipotent stem cells derived from the bone marrow, were effective in resolving pathology related to lung injury associated with influenza H5N1 infection.

In an in vitro co-culture model, alveolar epithelial cells (AECs) were grown with human MSCs or control human lung fibroblasts and assayed for their ability to perform critical functions of the lung epithelium. Co-culture with MSCs led to improved ability for AECs to transport fluid from their apical to basal side and increased the barrier function of the AEC monolayer against the passage of solutes. In aged mice infected with H5N1 virus, treatment with human MSCs enhanced survival rates and diminished the loss of body weight as a result of infection. As compared to animals treated with fibroblasts, MSC-injected mice had improved fluid transport functions and less protein accumulation in the bronchoalveolar lavage fluid.

This work provides groundwork for using MSCs to treat complications associated with acute viral infections. However, the safety of using allogeneic cells for clinical applications is currently being evaluated in several clinical trials. In addition to these results, more studies using MSC therapy in combination with traditional treatments of influenza infection will be useful in determining the overall impact of incorporating cell-based therapies as adjuvant treatment.

Click to read the study in PNAS

Relevant Reading: Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats

In-Depth [in vitro and animal study]: Human primary AECs were cultured on one side of a transwell insert, while the other side was seeded with human MSCs. After infection of AECs with H5N1 virus for 24 hours (multiplicity of infection=0.1), the net alveolar fluid transport was measured. Results indicated a significant increase in fluid transport from the apical to basolateral side of the AEC monolayer when cultured with MSCs versus control fibroblasts (p<0.01). These fluid clearance measurements with MSC co-culture were comparable to that of mock-infected AECs. Similarly, MSC co-culture led to a significant decrease in the permeability of the AEC monolayer (p<0.01), as measured by the transport of fluorescently labeled 70kDa dextran across the AECs after 24 hours.

To test the effects of MSCs in vivo, aged (8-12 months of age) female Balb/C mice were intranasally inoculated with 106 TCID50 (50% tissue culture infective dose) of H5N1 486/97 virus. Human MSCs (5×105 cells/animal) or control NIH 3T3 mouse fibroblasts (5×105 cells/animal) were delivered intravenously 5 days after H5N1 infection. Survival and body weight of mice (n=50-51) were monitored over the course of 18 days, showing greater survival and less weight loss in the MSC group. On day 7 post-infection (day 2 after cell injection), the wet-to-dry weight ratio of lungs was measured. The MSC-treated cohort (n=3) had a significantly lower wet-to-dry ratio than the fibroblast group (n=3), indicating better fluid clearance in the MSC mice (p<0.05). Analysis of the protein content of the fluid collected after bronchoalveolar lavage of MSC- or fibroblast-treated mice (n=4 per group) indicated a significant decrease in lung permeability 7 days after MSC injection (p<0.005).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.